Bottom Line:
Continuing the BMO Healthcare Hidden Gems series, we hosted a call with Outset Medical (private), an emerging medical technology company set to disrupt the treatment of kidney failure with its Tablo device. Tablo is a “simple, flexible and untethered “ solution to shift the treatment paradigm for dialysis patients, creating a true consumer experience by utilizing digital health tools and reducing labor and infrastructure costs.
Key Points
Outset Medical is positioned to transform the $80-90 billion dialysis market (including $34 billion spent by Medicare each year, or 7% of the Medicare budget) by introducing a new on-demand and self-care treatment platform called Tablo for both acute (ICU) and chronic (in-center) dialysis treatment. The device’s key pillars include: 1) consumer design; 2) infrastructure free dialysis; and 3) wireless data transmission.
Read More: https://bmo.bluematrix.com/docs/shorthtml/1c451604-e151-4ab0-9655-e5d438882a00.html
Via: BMO Capital Markets Via: Crunchbase ... Via: WQAD 8 PHILADELPHIA – Each year, more than 300,000 people in the U.S. are diagnosed with carotid artery disease. Via: OncoMed Office of the President Established to Lead Company during Medical Leave Via: OncoMed Phase 1a Study Will Assess Novel Immuno-Oncology Therapeutic Candidate as a Single Agent in Solid Tumors Via: WKOW 27 MADISON (WKOW) -- A new procedure at a Madison hospital is aiming to reduce the risks for people with cardiovascular problems. Via: BusinessWire CLEVELAND--(BUSINESS WIRE)--Neuros Medical, Inc., a neuromodulation company, announced today the appointment of Tom Wilder as President and CEO. Atomico leads $8 million investment in Hinge Health to tackle back pain and other chronic injuries7/24/2017
Via: VentureBeat Hinge Health, a fledgling digital health startup that’s building hardware and software to tackle musculoskeletal (MSK) disorders, has raised $8 million in a Series A round of funding led by European VC giant Atomico, with participation from existing seed investors, including Eleven Two Capital and the Vertical Group. Via: MassDevice Silk Road Medical said today it raised $47 million in a new funding round to support its Enroute products designed for transcarotid artery revascularization procedures. Via: MarketWatch Technology is offering a new fix for one of the most confounding health-care challenges: getting patients with chronic disease to take better care of themselves. |
Archives
October 2023
|